Classic Hairy Cell Leukemia (HCL-C)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Classic Hairy Cell Leukemia

MalaCards integrated aliases for Classic Hairy Cell Leukemia:

Name: Classic Hairy Cell Leukemia 58
Leukemic Reticuloendotheliosis 58
Hairy Cell Leukemia 71
Hcl-C 58



1-9/1000000 (Europe, United States, United Kingdom, Iceland, Denmark) 1-9/100000 (Europe) <1/1000000 (Hong Kong) 58

Age Of Onset:

Adult 58


Orphanet: 58  
Rare haematological diseases

External Ids:

MESH via Orphanet 44 D007943
ICD10 via Orphanet 32 C91.4
UMLS via Orphanet 72 C0023443
Orphanet 58 ORPHA58017
UMLS 71 C0023443

Summaries for Classic Hairy Cell Leukemia

Orphanet: 58 A rare, slowly progressive, chronic leukemia characterized by presence of abnormal B-lymphocytes (medium sized with abundant irregular pale cytoplasm, hair-like cytoplasmic projections/ruffled cytoplasmic border, a round or bean-shaped nucleus and absent nucleoli) in the blood or bone marrow, spleen and peripheral blood pancytopenia, notable monocytopenia, and marked susceptibility to infection. The characteristic immunophenotype is CD11c+, CD25+, CD103+ and CD123+ with a BRAF mutation in most cases.

MalaCards based summary: Classic Hairy Cell Leukemia, also known as leukemic reticuloendotheliosis, is related to intrapelvic lymph node leukemic reticuloendotheliosis and reticuloendotheliosis, x-linked. An important gene associated with Classic Hairy Cell Leukemia is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase). The drugs Cladribine and 2-chloro-3'-deoxyadenosine have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, spleen and bone.

Related Diseases for Classic Hairy Cell Leukemia

Graphical network of the top 20 diseases related to Classic Hairy Cell Leukemia:

Diseases related to Classic Hairy Cell Leukemia

Symptoms & Phenotypes for Classic Hairy Cell Leukemia

Drugs & Therapeutics for Classic Hairy Cell Leukemia

Drugs for Classic Hairy Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Cladribine Approved, Investigational Phase 2, Phase 3 4291-63-8 20279
2 2-chloro-3'-deoxyadenosine Phase 2, Phase 3 14485373
Alemtuzumab Approved, Investigational Phase 2 216503-57-0
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
Ondansetron Approved, Withdrawn Phase 2 99614-02-5 4595
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 4112 126941
Busulfan Approved, Investigational Phase 2 55-98-1 2478
Melphalan Approved Phase 2 148-82-3 4053 460612
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
Adenosine Approved, Investigational Phase 2 58-61-7 60961
Pentostatin Approved, Investigational Phase 2 53910-25-1 439693
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
Obinutuzumab Approved, Investigational Phase 2 949142-50-1
Prednisone Approved, Vet_approved Phase 1, Phase 2 53-03-2 5865
Vemurafenib Approved Phase 2 918504-65-1 42611257
Triamcinolone Approved, Vet_approved Phase 2 124-94-7 31307
Acalabrutinib Approved, Investigational Phase 1, Phase 2 1420477-60-6 71226663 71226662
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4 254741536
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
Brentuximab vedotin Approved, Investigational Phase 1, Phase 2 914088-09-8
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
Iron Approved Phase 2 7439-89-6 29936
Deferasirox Approved, Investigational Phase 2 201530-41-8 214348 5493381
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
D-Phenylalanine Approved, Experimental, Investigational, Nutraceutical Phase 2 63-91-2, 673-06-3 6140 71567
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
Veliparib Investigational Phase 1, Phase 2 912444-00-9 11960529
Cordycepin Investigational Phase 2 73-03-0 248010
Daclizumab Investigational, Withdrawn Phase 2 152923-56-3
33 Neurotransmitter Agents Phase 2
34 Antiemetics Phase 2
35 Gastrointestinal Agents Phase 2
36 Dermatologic Agents Phase 2
37 Cyclosporins Phase 2
38 Antifungal Agents Phase 2
39 Interferon alpha-2 Phase 2
40 interferons Phase 2
41 Interferon-alpha Phase 2
42 Bendamustine Hydrochloride Phase 1, Phase 2
43 Antipsychotic Agents Phase 2
44 Anti-Anxiety Agents Phase 2
45 Psychotropic Drugs Phase 2
46 Folic Acid Antagonists Phase 2
47 Folate Phase 2
48 Vitamin B9 Phase 2
49 Anti-Asthmatic Agents Phase 2
50 Vitamin B Complex Phase 2

Interventional clinical trials:

(show top 50) (show all 95)
# Name Status NCT ID Phase Drugs
1 Daily Versus Weekly Administration of 2-Chlorodeoxyadenosine (CDA) in Patients With Hairy Cell Leukemia Completed NCT00003746 Phase 3 2-chlorodeoxyadenosine (CDA) daily;2-chlorodeoxyadenosine weekly
2 A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia Completed NCT01829711 Phase 3 Moxetumomab pasudotox;IV Bag Protectant for Moxetumomab pasudotox
3 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
4 Therapy Optimisation for the Treatment of Hairy Cell Leukemia Recruiting NCT02131753 Phase 2, Phase 3 Cladribine s.c. injection, HCL treatment
5 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
6 A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia Completed NCT00001567 Phase 2 Roferon-A
7 Rituximab (IDEC-C2B8, Mabthera) in Patients With Hairy Cell Leukemia Relapsing After Treatment With 2-Chlorodeoxyadenosine (CDA) Completed NCT00003757 Phase 2
8 Phase II Trial Of BL22 Immunotoxin In Hairy Cell Leukemia Completed NCT00074048 Phase 2 BL22
9 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
10 A Phase I/II Study of Syk Inhibitor Entospletinib (GS-9973) in Combination With Obinutuzumab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-Cell Malignancies Completed NCT03010358 Phase 1, Phase 2 Entospletinib
11 Addition of Pre- and Post-Transplant Rituximab for Patients Undergoing Non-myeloablative Allogeneic Hematopoietic Cell Transplantation With Relapsed or Refractory CD20+ B-Cell Malignancies Completed NCT00867529 Phase 2
12 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
13 A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
14 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Completed NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
15 A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil Completed NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
16 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
17 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
18 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
19 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
20 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
21 A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
22 Study on the Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia Completed NCT02157181 Phase 2 2CdA +/- Rituximab
23 A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
24 Phase II Study of 2-Chlorodeoxyadenosine (2CDA) Followed by Rituximab in Hairy Cell Leukemia Recruiting NCT00412594 Phase 2 Cladribine
25 Phase 2 Trial for Binimetinib for Patients With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant Recruiting NCT04322383 Phase 2 binimetinib
26 Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia Recruiting NCT01059786 Phase 2 Pentostatin;Rituximab;Bendamustine
27 Randomized Trial of Cladribine (CdA) With Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease Recruiting NCT00923013 Phase 2 Cladribine;Rituximab
28 A Single Arm Phase II Pilot Study of Low Dose Vemurafenib Plus Rituximab in the Front-line and Relapsed/Refractory Treatment of Hairy Cell Leukemia Recruiting NCT05388123 Phase 2 Low dose vemurafenib plus rituximab
29 A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25) Recruiting NCT05537766 Phase 2 Cyclophosphamide;Fludarabine
30 Phase 2 Trial of Encorafenib Plus Binimetinib for Patients With BRAF V600 Mutated Relapsed/Refractory HCL Recruiting NCT04324112 Phase 2 binimetinib;Encorafenib
31 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
32 A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia Active, not recruiting NCT01841723 Phase 2 Ibrutinib
33 Prospective, Multi-center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas Active, not recruiting NCT02213913 Phase 1, Phase 2 lenalidomide;etoposide;prednisone;vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide
34 A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia Active, not recruiting NCT03410875 Phase 2 Vemurafenib;Obinutuzumab
35 A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for CD25 Positive Hairy Cell Leukemia Active, not recruiting NCT00321555 Phase 2 Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin
36 A Phase II Study of the BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia Active, not recruiting NCT01711632 Phase 2 Vemurafenib
37 A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects With Hematologic Malignancies Active, not recruiting NCT02362035 Phase 1, Phase 2 Acalabrutinib;Pembrolizumab
38 A Phase II Study of Sunitinib Malate in Idiopathic Myelofibrosis Terminated NCT00387426 Phase 2 sunitinib malate
39 A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas Terminated NCT01805037 Phase 1, Phase 2 brentuximab vedotin
40 Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia Terminated NCT00924040 Phase 2 BL22 (CAT-3888)
41 Phase I/II Study of Anti-CTLA-4 Monoclonal Antibody (MDX-010) in B-cell Non-Hodgkin's Lymphoma Terminated NCT00089076 Phase 1, Phase 2
42 Deferasirox Treatment and Labile Plasma Iron in Iron Overloaded Patients Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01159067 Phase 2 deferasirox
43 A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL/SLL/PLL or NHL With Lenalidomide Alone or With Rituximab Terminated NCT01419795 Phase 2 lenalidomide
45 A Phase 2 Study to Evaluate the Anti-Tumor Activity of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies Withdrawn NCT03739606 Phase 2
46 A Phase I/II Trial of Romidepsin, Rituximab and Lenalidomide (R3) in Relapsed/Refractory B Cell Lymphomas Including Transformed Follicular Lymphoma Withdrawn NCT02281279 Phase 1, Phase 2 lenalidomide;romidepsin
47 Hematopoietic Stem Cell Transplantation Using Alternate Donor Umbilical Cord Blood Options Withdrawn NCT01652014 Phase 2 cyclophosphamide;fludarabine phosphate;mycophenolate mofetil;tacrolimus
48 A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patient With Relapsed or Refractory Hairy Cell Leukemia (HCL) Unknown status NCT00462189 Phase 1 Immunotoxin therapy;CAT-8015 Immunotoxin
49 A Phase I Study of Flavopiridol, Fludarabine and Rituximab in Indolent B-cell Lymphoproliferative Disorders and Mantle Cell Lymphoma Completed NCT00058227 Phase 1 alvocidib;fludarabine phosphate
50 A Phase I Pharmacokinetic Study of STI571 in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction Completed NCT00025415 Phase 1 imatinib mesylate

Search NIH Clinical Center for Classic Hairy Cell Leukemia

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Interferon Alfa-2a
Interferon Alfa-2b
interferon alfacon-1
Interferon gamma-1b
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b

Genetic Tests for Classic Hairy Cell Leukemia

Anatomical Context for Classic Hairy Cell Leukemia

Organs/tissues related to Classic Hairy Cell Leukemia:

MalaCards : Bone Marrow, Spleen, Bone, T Cells, Liver, B Cells, Ovary

Publications for Classic Hairy Cell Leukemia

Articles related to Classic Hairy Cell Leukemia:

(show top 50) (show all 195)
# Title Authors PMID Year
Protein profiling by reverse phase protein array (RPPA) in classical hairy cell leukemia (HCL) and HCL-variant. 62
36467805 2022
Intracavity absorption spectroscopy of HCl isotopes, H2O, CH4, C2H4, and C2H6 in the 3.1-3.4 µm spectral range using a Cr:CdSe laser. 62
36298969 2022
Synthesis and structure of clozapine N-oxide hemi(hydro-chloride): an infinite hydrogen-bonded poly[n]catenane. 62
36250113 2022
[Classic hairy cell leukemia with MAP2K1 mutation: a case report]. 62
35680604 2022
Rotational Mode-Specificity in the Cl + C2H6 → HCl + C2H5 Reaction. 62
35427141 2022
Hairy Cell Leukemia Patients Have a Normal Life Expectancy-A 35-Year Single-Center Experience and Comparison with the General Population. 62
35267550 2022
Treatment of Classic Hairy Cell Leukemia: Targeting Minimal Residual Disease beyond Cladribine. 62
35205704 2022
Advances in the Treatment of Hairy Cell Leukemia Variant. 62
35178674 2022
Vibrational mode-specificity in the dynamics of the Cl + C2H6 → HCl + C2H5 reaction. 62
34551541 2021
Effects of lycopene intake on HDL-cholesterol and triglyceride levels: A systematic review with meta-analysis. 62
34268742 2021
The Biology of Classic Hairy Cell Leukemia. 62
34360545 2021
The Influence of HCl Concentration on the Rate of the Hydrolysis-Condensation Reaction of Phenyltrichlorosilane and the Yield of (Tetrahydroxy)(Tetraphenyl)Cyclotetrasiloxanes, Synthesis of All Its Geometrical Isomers and Thermal Self-Condensation of Them under "Pseudo"-Equilibrium Conditions. 62
34299658 2021
Classic hairy cell leukemia with an aggressive presentation. 62
34733001 2021
Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant. 62
33727830 2021
A BRAF-Negative Classic Hairy Cell Leukemia Patient with Long-Lasting Complete Remission after Rituximab and Pentostatin 62
32539314 2020
Hydrochloric acid corrosion induced bifunctional free-standing NiFe hydroxide nanosheets towards high-performance alkaline seawater splitting. 62
33094769 2020
BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials. 62
31740808 2020
Difference of genomic copy numbers alterations between hairy cell leukemia-variant and classical hairy cell leukemia: a pilot retrospective study in Chinese. 62
32132867 2020
A Study of the Influence of the HCl Concentration on the Composition and Structure of (Hydroxy)Arylsiloxanes from the Hydrolysis-Condensation Reaction of Aryltrichlorosilanes. 62
31752317 2019
Non covalent interactions stabilizing the chiral dimer of CH2ClF: a rotational study. 62
30652707 2019
Pyrolysis of blend (oil palm biomass and sawdust) biomass using TG-MS. 62
30553084 2019
Genome-wide promoter methylation of hairy cell leukemia. 62
30723113 2019
[Hairy cell leukemia complicated by bone marrow necrosis following cladribine administration]. 62
31281144 2019
Classic hairy cell leukemia complicated by pancytopenia and severe infection: a report of 3 cases treated with vemurafenib. 62
30630817 2019
Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience. 62
29955146 2018
New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes. 62
29989027 2018
Survival and detection of Bacillus cereus in the presence of Escherichia coli, Salmonella enteritidis, Staphylococcus aureus, Pseudomonas aeruginosa and Candida albicans after rechallenge in make-up removers. 62
29030872 2018
2-(Trimethylsilyl)-λ3 -Phosphinine: Synthesis, Coordination Chemistry, and Reactivity. 62
29068102 2018
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. 62
27903528 2017
What is the association of lipid levels and incident stroke? 62
27400190 2016
Intravaginal administration of metformin hydrochloride loaded cationic niosomes amalgamated with thermosensitive gel for the treatment of polycystic ovary syndrome: In vitro and in vivo studies. 62
27085048 2016
"Conformational lock"via unusual intramolecular C-FO[double bond, length as m-dash]C and C-HCl-C parallel dipoles observed in in situ cryocrystallized liquids. 62
27149236 2016
Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13(7):609-630. 62
27013208 2016
Long-term treatment of hairy cell leukemia with interferon-α: still a viable therapeutic option. 62
27429657 2016
BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation. 62
26350141 2015
Relative stabilities of HCl•H2SO4•HNO3 aggregates in polar stratospheric clouds. 62
25758341 2015
Organotin-oxido cluster-based multiferrocenyl complexes obtained by hydrolysis of ferrocenyl-functionalized organotin chlorides. 62
25164865 2014
Current therapeutic options in hairy cell leukemia. 62
24971416 2014
Diurnal glucose profiles using continuous glucose monitoring to identify the glucose-lowering characteristics of colesevelam HCl (Welchol). 62
23598534 2013
A hairy cell leukaemia variant - a rare case report. 62
23543122 2013
[Analysis of clinical and laboratory characteristics and survival with hairy cell leukemia]. 62
23328507 2012
Anti-hepatitis C virus activity of 3-hydroxy caruilignan C from Swietenia macrophylla stems. 62
22497816 2012
Management of hairy cell leukemia variant. 62
21599606 2011
Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. 62
20558005 2011
Classical hairy cell leukemia and its variant: a 17-year retrospective survey in Taiwan Chinese. 62
21846972 2011
Experimental and computational investigation of C-N bond activation in ruthenium N-heterocyclic carbene complexes. 62
21128626 2010
Primary photodissociation pathways of epichlorohydrin and analysis of the C-C bond fission channels from an O((3)P)+allyl radical intermediate. 62
20831317 2010
How I treat hairy cell leukemia. 62
19843881 2010
[Effect of hawthorn flavanone on blood-fat and expression of lipogenesis and lipolysis genes of hyperlipidemia model mouse]. 62
19385191 2009
Photocatalytic degradation of dichloromethane by chlorocuprate(II) ions. 62
18593110 2008

Variations for Classic Hairy Cell Leukemia

Expression for Classic Hairy Cell Leukemia

Search GEO for disease gene expression data for Classic Hairy Cell Leukemia.

Pathways for Classic Hairy Cell Leukemia

GO Terms for Classic Hairy Cell Leukemia

Sources for Classic Hairy Cell Leukemia

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....